Table 1 Patients’ characteristics and the survival results in the patients with baseline plasma samples available compared with the overall study population
From: Neuropilin-1 and placental growth factor as prognostic factors in metastatic breast cancer
Baseline plasma population (n = 53) | Overall study population (n = 65) | |
|---|---|---|
Age, years | ||
Median (range) | 58 (32–75) | 57 (32–75) |
Menopausal status, n (%) | ||
Pre-menopausal Post-menopausal | 8 (15.1) 45 (84.9) | 10 (15.4) 55 (84.6) |
Hormone receptor status, n (%) | ||
ER + and/or PR+ ER- and PR- | 43 (81.1) 10 (18.9) | 53 (81.5) 12 (18.5) |
Extent of disease | ||
< 3 sites ≥ 3 sites | 31 (58.5) 22 (41.5) | 39 (60.0) 26 (40.0) |
Site of metastatic disease, n (%) | ||
Visceral disease Non-visceral disease | 41 (77.4) 12 (22.6) | 53 (81.5) 12 (18.5) |
Median overall survival, months (95% CI) | 39.2 (26.7–51.7) | 35.1 (22.2–50.3) |
Median progression-free survival, months (95% CI) | 11.2 (8.4–14.1) | 11.3 (9.7–16.0) |